Company intelligence / Profile preview

Barer & Son Capital

Mendham, New Jersey, United States

Ownership: Private
Development stage: Other

Overview

Barer & Son Capital is a life science venture capital fund managed by Hibiscus Capital Management. It invests primarily in biotechnology, diagnostics, therapeutics, and biopharma companies, with notable investments including portfolio exits through IPO such as NexImmune. The fund does not itself develop drugs but backs early- and growth-stage companies in the sector.[1][3]

Industry: Investors

Beyond the preview

Go deeper on Barer & Son Capital.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Barer & Son Capital.

Explore the full profile